Skip to search formSkip to main contentSkip to account menu

LY 450139

Known as: LY-450139, LY450139 
National Institutes of Health

Related topics

Related topics

1 relation
Semagacestat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Pharmacological properties of a novel and potent γ-secretase modulator as a therapeutic option for the treatment of Alzheimer’s disease
2016
2016
A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
In Alzheimer’s disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is… 
Review
2012
Review
2012
Evaluation of the Performance of Novel Aβ Isoforms as Theragnostic Markers in Alzheimer’s Disease: From the Cell to the Patient
Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the aging population and is characterized… 
2010
2010
ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
Semagacestat (LY450139) is a novel γ-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a… 
Review
2008
Review
2008
Recent progress in the medicinal chemistry of gamma-secretase inhibitors.
Abeta is implicated in the initiation and progression of Alzheimer's disease (AD) by the phenotypic analysis of mutations in… 
Highly Cited
2006
Highly Cited
2006
Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
LY-450139 is a gamma-secretase inhibitor shown to have efficacy in multiple cellular and animal models. Paradoxically, robust… 
2006
2006
Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease”
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2002
2002
γ-Secretase inhibitors and Alzheimer’s disease
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)